<DOC>
	<DOCNO>NCT00802360</DOCNO>
	<brief_summary>To compare efficacy safety highly purified menotropin ( Menopur® ) follitropin beta ( FOLLISTIM® ) patient undergo gonadotropin-releasing hormone ( GnRH ) antagonist vitro fertilization ( IVF ) cycle</brief_summary>
	<brief_title>MENOPUR® Versus FOLLISTIM®</brief_title>
	<detailed_description>This multicenter , randomize , open-label exploratory study perform approximately 200 healthy female undergo vitro fertilization ( IVF ) . Each study center follow study center standard practice vitro fertilization ( IVF ) within study parameter note protocol . The study center use market product purchase Schraft 's Pharmacy phase study ( down-regulation , stimulation , ovulation induction , luteal support ) . Subjects randomly assign prior start stimulation highly purify menotropin ( Menopur® ) follitropin beta ( Follistim Pen® ) stimulation progesterone vaginal insert ( Endometrin® ) progesterone oil luteal support . Subjects return study center regular schedule clinic visit require per vitro fertilization ( IVF ) protocol site specify time period cycle estradiol ( E2 ) , progesterone ( P4 ) human chorionic gonadotropin ( hCG ) test , first serum pregnancy test . All subject require complete final study visit completion luteal support negative serum pregnancy test follow embryo transfer .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>1 . Premenopausal females age 18 42 year 2 . Body mass index ( BMI ) 1834 3 . Early follicular phase ( day 24 ) Follicle stimulate hormone ( FSH ) &lt; 15 IU/L Estradiol ( E2 ) within normal limit 4 . Documented history infertility ( e.g. , unable conceive least one year , 6 month woman &gt; 38 year age , bilateral tubal occlusion absence , male factor exclude severe male factor require invasive surgical sperm retrieval . Donor sperm may use . ) 5 . Transvaginal ultrasound screen consistent finding adequate assist reproductive technology ( ART ) respect uterus adnexa 6 . Signed informed consent 1 . Gestational surrogate carrier , donor oocyte 2 . Presence clinically relevant systemic disease ( e.g. , insulindependent diabetes mellitus , uterine cancer ) 3 . Surgical medical condition , judgment Investigator Sponsor , may interfere absorption , distribution , metabolism , excretion drug use 4 . Previous In vitro fertilization ( IVF ) Assisted reproductive technology ( ART ) failure due poor response gonadotropin . Poor response define development 2 mature follicle history &gt; 2 previous fail vitro fertilization ( IVF ) cycle . 5 . History recurrent pregnancy loss ( &gt; 2 ) . 6 . Presence abnormal uterine bleeding undetermined origin 7 . Current recent substance abuse , include alcohol smoking &gt; 10 cigarette per day 8 . Refusal inability comply requirement Protocol reason , include schedule clinic visit laboratory test 9 . Participation experimental drug study within 30 day prior Screening 10 . Severe male factor require invasive surgical sperm retrieval ( e.g. , microsurgical epididymal sperm aspiration [ MESA ] , testicular sperm extraction [ TESE ] )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Healthy , pre-menopausal woman , age 18-42 history infertility require IVF</keyword>
</DOC>